The clinical trials evaluating ATR inhibitor+anti-PD-1 combination did not report obvious overlapping toxicities.20 21 46 Given that oxaliplatin induces hematological and neurological toxicities, and ATR inhibitors mainly hematological toxicities (anemia, myelosuppression), a mitigation of the toxicity (anemia, hematological toxicities, myelosuppression) can be expected when we combine oxaliplatin to ATR inhibitor. This evidence concerns the gene ATR and anemia.